Rare diseases
Investigational molecules
Locations
Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
BelgiumStudy of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
BelgiumA study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis
GermanyStudy on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease
BelgiumStudy on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease
BelgiumComparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis
BulgariaStudy of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis
BulgariaStudy of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis
GermanyStudy on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis
BulgariaA study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa
FranceA Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is
FranceStudy on the Effectiveness and Safety of Zasocitinib (TAK-279) for Patients with Active Psoriatic Arthritis with Previous Biologic Treatment
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
